Table 21:
Scenario Analysis Results - Comparing HCV Screening Strategies in All Adults and in the 1945-1975 Birth Cohort (Results per Person)
| Uptake of HCV antibody testing | Strategy | Average total cost, $ | Incremental cost, $a,b,c |
Average total QALYs | Incremental QALYc,d |
ICERc |
|---|---|---|---|---|---|---|
| All adults | ||||||
| 1.1 times increase in intervention | Risk-based HCV screening | 289,701.76 | − | 22.8245 | − | − |
| HCV screening of all adults plus risk-based screening | 289.695.25 | −6.51 | 22.8247 | 0.0002 | Dominante | |
| 1945-1975 birth cohort | ||||||
| 1.1 times increase in intervention | Risk-based HCV screening | 308,996.75 | − | 16.6774 | − | − |
| HCV screening of the 1945-1975 birth cohort plus risk-based screening | 308,994.11 | −1.64 | 16.6774 | 0.0001 | Dominante | |
Abbreviation: HCV, hepatitis C virus; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
a
Incremental cost = average cost (strategy B) - average cost (strategy A).
b
Negative costs indicate savings.
c
Results may appear inexact due to rounding.
d
Incremental effect = average effect (strategy B) - average effect (strategy A).
e
HCV screening of all adults plus risk-based screening and HCV screening of the 1945-1975 birth cohort plus risk-based screening were both less costly and more effective than risk-based screening alone.